1. Home
  2. IGMS vs AAM Comparison

IGMS vs AAM Comparison

Compare IGMS & AAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGMS
  • AAM
  • Stock Information
  • Founded
  • IGMS 1993
  • AAM 2024
  • Country
  • IGMS United States
  • AAM United States
  • Employees
  • IGMS N/A
  • AAM N/A
  • Industry
  • IGMS Biotechnology: Pharmaceutical Preparations
  • AAM
  • Sector
  • IGMS Health Care
  • AAM
  • Exchange
  • IGMS Nasdaq
  • AAM Nasdaq
  • Market Cap
  • IGMS 528.6M
  • AAM 441.9M
  • IPO Year
  • IGMS 2019
  • AAM 2024
  • Fundamental
  • Price
  • IGMS $7.48
  • AAM $10.09
  • Analyst Decision
  • IGMS Buy
  • AAM
  • Analyst Count
  • IGMS 8
  • AAM 0
  • Target Price
  • IGMS $16.25
  • AAM N/A
  • AVG Volume (30 Days)
  • IGMS 213.0K
  • AAM 447.8K
  • Earning Date
  • IGMS 11-08-2024
  • AAM 01-01-0001
  • Dividend Yield
  • IGMS N/A
  • AAM N/A
  • EPS Growth
  • IGMS N/A
  • AAM N/A
  • EPS
  • IGMS N/A
  • AAM N/A
  • Revenue
  • IGMS $2,918,000.00
  • AAM N/A
  • Revenue This Year
  • IGMS $386.95
  • AAM N/A
  • Revenue Next Year
  • IGMS N/A
  • AAM N/A
  • P/E Ratio
  • IGMS N/A
  • AAM N/A
  • Revenue Growth
  • IGMS 57.64
  • AAM N/A
  • 52 Week Low
  • IGMS $6.17
  • AAM $9,600.00
  • 52 Week High
  • IGMS $22.50
  • AAM $15,000.00
  • Technical
  • Relative Strength Index (RSI)
  • IGMS 31.94
  • AAM N/A
  • Support Level
  • IGMS $7.00
  • AAM N/A
  • Resistance Level
  • IGMS $10.80
  • AAM N/A
  • Average True Range (ATR)
  • IGMS 1.02
  • AAM 0.00
  • MACD
  • IGMS -0.10
  • AAM 0.00
  • Stochastic Oscillator
  • IGMS 10.39
  • AAM 0.00

About IGMS IGM Biosciences Inc.

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

About AAM AA Mission Acquisition Corp. Class A Ordinary Shares

AA Mission Acquisition Corp is a blank check company.

Share on Social Networks: